Mylan Shareholders Reject Drugmaker's Executive Pay Package
- Vote marks second time since 2011 holders voted against pay
- Shareholders approved all directors nominated to Mylan board
This article is for subscribers only.
A majority of Mylan NV investors voted against the drugmaker’s 2016 compensation program following a $97.6 million reported package for Chairman Robert Coury and controversy over prices for the company’s EpiPen allergy treatment.
The vote marks the second time that a majority of investors have rejected the company’s pay program since Mylan first held advisory votes on executive compensation in 2011. Shareholders also voted to approve all board nominees on Thursday at Mylan’s annual meeting in Amsterdam.